51results about How to "Promote nerve regeneration" patented technology

Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents such as AG1478 to induce nerve regeneration, specifically regeneration of the optic nerve useful for managing elevated intraocular pressure (TOP) in the eye.

A nerve regeneration stimulator comprising a compound having a cholinesterase inhibitory activity, a pharmacologically acceptable salt thereof or a solvate thereof.

A novel use of periostin, and more particularly a composition for inducing the migration of neural stem cells, which contains periostin or a periostin-secreting cell as an active ingredient, based on the discovery of a novel function of periostin that induces the migration of neural stem cells. Periostin induces the migration of neural stem cells, and thus the composition for inducing the migration of neural stem cells, which contains periostin or periostin-secreting cells as an active ingredient, can be used in various applications based on neural stem cells. A pharmaceutical composition containing suicide gene-expressing neural stem cells and periostin allows the neural stem cells to effectively migrate to tumor tissues, and thus can be used as a cell therapeutic agent for treating cancer. Also, the pharmaceutical composition containing neural stem cells and periostin has improved effects on the stimulation of regeneration of nerve cells and the treatment of neural diseases.

The invention provides an eye-drop vaccine for therapeutic immunization of a mammal comprising Copolymer 1, a Copolymer 1-related peptide, or a Copolymer 1-related polypeptide, for treating neuronal degeneration caused by an injury or disease, disorder or condition in the central nervous system (CNS) or peripheral nervous system (PNS), for preventing or inhibiting neuronal secondary degeneration which may otherwise follow primary injury in the CNS, for promoting nerve regeneration in the CNS or in the PNS after an injury, disease, disorder or condition or for protecting CNS and PNS cells from glutamate toxicity.

This application discloses a composite material comprising one or more silk elements in an acrylic or cross-linked protein matrix. The silk elements are made from the group of silk elements consisting of domestic silkworm silk, wild silkworm silk, spider dragline silk, and filaments spun from recombinant silk protein or protein analogues. The composite material is particularly useful for use in-surgical-implants.

The invention, which relates to the technical field of biomedicine, provides a piezoelectric stent composition capable of realizing self-generating electricity stimulation as well as a preparation method and application thereof. The composition is composed of a biodegradable metabolic material and a piezoelectric material. With a 3D printing, jetting, pouring, extruding, die forming or electrostatic spinning method, the co-melt of the biodegradable material and the piezoelectric material or an organic solvent is formed into various biomedical application stents, especially nerve conduit stents. According to the invention, the mechanical energy in an in-vivo environment can be into electrical stimulation to promote regeneration, proliferation and differentiation of nerves, muscles, bones, blood vessels and the like without implantation of an external power supply or an electrode. The piezoelectric stent composition has advantages of being simple to prepare, low in cost, easy to controlin quality, wide in application range and the like. Rat in-vivo experiments show that the piezoelectric catheter stent has functions of promoting nerve regeneration and angiogenesis, relieving muscleatrophy and the like and has the broad clinical application prospects.

The invention discloses a chitosan artificial nerve graft containing a neurotrophic factor and a preparation method thereof. The chitosan artificial nerve graft is prepared by processing chitosan into a nerve conduit with a porous structure and high tensile strength by virtue of weak acid dissolution, mold injection, freezing formation, neutralization and immobilization, cleaning, lyophilization and other processes under a condition of not adding any foaming agent or cross linking agent. The cell factor with a treatment effect in the nerve conduit is one or more of a basic fibroblast growth factor (bFGF), a brain derived neurotrophic factor (BDNF), a neurotrophic factor 3 (NT-3), a basic fibroblast cell growth factor (bFGF) and a glial-cell-line derived neurotrophic factor (GDNF) and the like. The product provided by the invention contains the neurotrophic factor, adopts degradable materials, and has excellent biocompatibility with a human body. The prepared product does not contain exogenous toxic or side-effect substances brought by a preparation process.

This application discloses a composite material comprising one or more silk elements in an acrylic or cross-linked protein matrix. The silk elements are made from the group of silk elements consisting of domestic silkworm silk, wild silkworm silk, spider dragline silk, and filaments spun from recombinant silk protein or protein analogues. The composite material is particularly useful for use in-surgical-implants.

The invention discloses an M2 type bone marrow macrophage exosome, application thereof and a spinal cord injury treatment preparation, and belongs to the technical field of spinal cord injury treatment. The M2 type bone marrow macrophage exosome highly expressing the OTULIN protein can play roles in improving a local ischemia and hypoxia environment after spinal cord injury and promoting revascularization, and is more beneficial to nerve regeneration and survival of local tissues. An exosome sustained-release system is formed by combining with light-cured hydrogel and is applied to local spinal cord injury, so that the treatment efficiency of the exosome is improved, liver and kidney metabolism is avoided, long-time action can be realized by continuous sustained release, and functional recovery of mice after spinal cord injury is remarkably improved.

A PKB (Akt) activating agent comprising a compound represented by the formula (I): wherein R1 and R2: H, a hydrocarbon group or a heterocyclic group or R1 and R2 form a ring in cooperation with the adjacent carbon atom; R3: H, a hydrocarbon group or a heterocyclic group; W: represents a group represented by the formulas: wherein ring A: an optionally substituted benzene ring; ring B: an optionally substituted 5- to 7-membered nitrogen-containing heterocycle; R4: an aliphatic hydrocarbon group substituted with an aromatic group and further optionally substituted, or an acyl group containing an aromatic group; R5: H, C1-6 alkyl or acyl; R4c: an aromatic group, an aliphatic hydrocarbon group or acyl; and X:O or S; Y:O, S or NH; and ring C: an optionally substituted benzene ring, or a salt or a prodrug thereof, and use of the activating agent in prevention or treatment of depression, anxiety, manic-depressive psychosis or PTSD are provided.

The invention relates to a degradable composite nerve conduit and a preparation method thereof, and belongs to the technical field of medical biomaterials. The degradable composite nerve conduit comprises the following materials: polylactic acid-glycolic acid, hyaluronic acid, silk fibroin, collagen and heparin. With natural materials and synthetic high molecular materials as raw materials, according to an electrospinning technology, the nerve conduit adopting a composite structure and having good biocompatibility, mechanical properties and degradability is prepared; the nerve conduit adopts abiomimetic structure and can simulate an extracellular matrix, so that cell adhesion, proliferation and migration inside the conduit are facilitated and nerve regeneration is promoted.

A PKB (Akt) activating agent comprising a compound represented by the formula (I): wherein R1 and R2: H, a hydrocarbon group or a heterocyclic group or R1 and R2 form a ring in cooperation with the adjacent carbon atom; R3: H, a hydrocarbon group or a heterocyclic group; W: represents a group represented by the formulas: wherein ring A: an optionally substituted benzene ring; ring B: an optionally substituted 5- to 7-membered nitrogen-containing heterocycle; R4: an aliphatic hydrocarbon group substituted with an aromatic group and further optionally substituted, or an acyl group containing an aromatic group; R5: H, C1-6 alkyl or acyl; R4c: an aromatic group, an aliphatic hydrocarbon group or acyl; and X: O or S; Y: O, S or NH; and ring C: an optionally substituted benzene ring, or a salt or a prodrug thereof, and use of the activating agent in prevention or treatment of depression, anxiety, manic-depressive psychosis or PTSD are provided.

Methods and compositions are provided for transgene expression in target cells. Expression constructs using an inducible amplification system to drive expression of a therapeutic gene or other gene of interest in mammalian host cells are provided, as well as methods therefor. Inducible expression of the transgenes at high levels under physiologic conditions results from induction by hyperthermic conditions relative to the basal temperature of the host cells.

The invention discloses a medicinal composition for nerve regeneration after ischemic cerebral stroke and application thereof, the medicinal composition is an oral preparation comprising an active ingredient and a medicinal supplementary material, wherein the active ingredient is N'-(2-(1H-indole-3-yl) acetyl)-2-iodobenzoyl hydrazine. The medicinal composition can increase the expression of a nerve growth positive regulation factor to inhibit the expression of a nerve growth negative regulation factor to promote the nerve regeneration process after the ischemic cerebral stroke so as to promote the rehabilitation of motor functions.

A nerve regeneration device comprising a support structure having an outer surface and a plurality of conduits extending therethrough, the support structure comprising a first extracellular matrix (ECM) material from a mammalian tissue source, the support structure outer layer including at least a first layer comprising a first ECM composition having at least a second ECM material from a mammalian tissue source. When the nerve regeneration device is deployed proximate damaged neural tissue, the device induces modulated healing of the damaged tissue.

Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents such as AG1478 to induce nerve regeneration, specifically regeneration of the optic nerve useful for managing elevated intraocular pressure (IOP) in the eye.

The present invention relates to an FK506 derivative which has reduced immunosuppressive activity but maintains nerve regeneration activity, a preparing method thereof, and a pharmaceutical composition comprising the same for preventing or treating nervous system diseases. A composition comprising 9-deoxo-prolyl-FK506, 31-O-demethyl-FK506, or 9-deoxo-31-O-demethyl-FK506 can promote nerve regeneration and has reduced immunosuppressive activity, thereby reducing side effects in the treatment of nervous system diseases.

The present invention discloses a biofilm capable of rapidly recovering skin wound surface, and a preparation method thereof, wherein the biofilm is prepared from an endothelial progenitor cell serum-free medium liquid and calcium alginate. The specific preparation steps comprise: 1) separating cells from a monocyte layer, inoculating in a culture bottle, carrying out primary culture, completely replacing the culture liquid on the 4th day, and replacing the culture liquid every 2-3 days later; 2) carrying out subculturing after the cells grow to achieve 70-80% fusion; 3) culturing the cells to achieve the 3-5 generation cells, replacing the culture liquid, and carrying out hypoxia induction; 4) carrying out reoxygenation culture on the cells obtained in the step 3) after replacing with a serum-free culture liquid; and 5) carrying out centrifugal filtration, collecting the culture liquid, and preparing a calcium alginate composite biofilm by using a freeze-drying method. According to the present invention, the preparation scheme has characteristics of simpleness, easy performing, low cost, high efficiency, good diabetes wound surface treatment effect, and long-term storage.

The present invention relates to an FK506 derivative which has reduced immunosuppressive activity but maintains nerve regeneration activity, a preparing method thereof, and a pharmaceutical composition comprising the same for preventing or treating nervous system diseases. A composition comprising 9-deoxo-prolyl-FK506, 31-O-demethyl-FK506, or 9-deoxo-31-O-demethyl-FK506 can promote nerve regeneration and has reduced immunosuppressive activity, thereby reducing side effects in the treatment of nervous system diseases.

The invention relates to the field of medicine for treating newborn cerebral hemorrhage, in particular to application of II type cannabinoid receptor stimulant in preparation of medicine for treating newborn cerebral hemorrhage. The application of the II type cannabinoid receptor stimulant in preparation of medicine for promoting nerve regeneration, neural precursor cell differentiation and neural stem cell proliferation after treating newborn cerebral hemorrhage is provided. It is found through tests that the II type cannabinoid receptor stimulant has the effects of promoting newborn nerve regeneration, neural precursor cell differentiation and neural stem cell proliferation; in addition, GMH-induced hydrocephalus can be remarkably reduced. In addition, the II type cannabinoid receptor stimulant is used in cooperation with minocyline which can remarkably increase transmittance of the blood brain barrier of the II type cannabinoid receptor stimulant and add the anti-inflammation effect treatment effect.

The invention is suitable for the field of selenium-containing compounds, and provides application of selenomethionine. The application is applying the selenomethionine to preparation of a medicine / health-care product for promoting nerve regeneration. The application of the selenomethionine provided by the embodiment has the advantages that the selenomethionine is used for preparing the medicine / health-care product for promoting nerve regeneration, and the therapy effect on the nerve regeneration of animals is obvious; a certain prevention and therapy function on neurodegenerative disease or nerve system injury is realized, and significant meaning on restoration of nerve system and improvement of memory and cognition is realized.

The present invention relates to a fibrous nerve conduit for promoting nerve regeneration, comprising a channel, the channel having diameter controllable ends, the channel is adjustable to suturing to a proximal and distal end of a severed nerve, the conduit further comprises a PCL (MW: 70 KDa) with concentration of 10-15% and PLGA (MW: 50 KDa, 50:50) with concentration of 10-18%.

The invention discloses a sodium alginate hydrogel for promoting wound healing and a preparation method of the sodium alginate hydrogel. The sodium alginate hydrogel is prepared from a serum-free medium of endothelial progenitor cells. Specifically, the preparation method comprises the following steps: 1) separating cells in a mononuclear cell layer, inoculating a culture flask with the cells and conducting primary culture, completely changing a medium on the 4th day and changing the medium once every other 2-3 days; 2) conducting subculture when the cells grow to 70-80% fusion; 3) culturing the cells to 3rd-5th generations, changing the medium and conducting hypoxia inducing; 4) conducting re-oxygenation culture on the cells obtained from induced culture after the serum-free medium is changed; and 5) conducting centrifuging and filtering, and collecting a medium, so that the serum-free conditioned cell medium, namely the sodium alginate hydrogel, is prepared. The preparation scheme is convenient and easy to operate, low in cost and high in efficiency; for wound surfaces, the sodium alginate hydrogel has a good therapeutic effect; and the sodium alginate hydrogel can be preserved for a long time.

The invention discloses a pharmaceutical composition for promoting stroke patient nerve regeneration and a use thereof. The pharmaceutical composition is an oral preparation and is prepared from an active component and pharmaceutic adjuvants. The active component is a N'-(2-(1H-indolyl-3-yl)acetyl)arylhydrazide compound shown in the formula. The pharmaceutical composition can inhibit nerve growth negative regulation and control factor expression through improving nerve growth positive regulation and control factor expression, promote nerve regeneration after stroke and promotes motion function recovery.

The invention discloses freeze-dried powder used for promoting healing of a diabetic wound and a preparing method thereof. The freeze-dried powder is made by freeze-drying a serum-free nutrient solution in an endothelial progenitor cell. The preparing method specifically comprises the steps of separating cells with mononuclear cell layers, inoculating the cells in a culture flask to be subjected to preliminary cultivation, changing a culture solution in a whole-content mode in the fourth day, and afterwards changing the culture solution once every 2-3 days; conducting continuous cell culture after the cells grows until 70-80% of the cells fuse; culturing the cells to the third to fifth generation, and changing the culture solution to be subjected to hypoxia inducing; conducting reoxygenation cultivation on the inducing cultured cells after changing the culture solution into the serum-free culture solution; conducting centrifugal filtration on the culture solution, collecting the culture solution, and conducing concentration and freeze-drying on the culture solution. The preparing method is simple, convenient and easy to operate, low in cost, high in efficiency and good in wound treating effect of diabetes, and the freeze-dried powder can be stored for a long time.

The invention discloses a Tibetan medicine composition for treating stroke caused by stagnation of phlegm and blood. The composition is obtained by reducing on the basis of the prescription of an original Zhenlongxingnao capsule, exactly 29 medicines in the original Zhenlongxingnao capsule prescription is reduced to 9 medicines. Based upon animal tests, the composition disclosed by the invention is concrete in curative effect, and the composition is capable of effectively treating the stroke caused by stagnation of phlegm and blood and promoting angiogenesis and nerve regeneration of experimental rats; and compared with the original Zhenlongxingnao capsule, the Tibetan medicine composition can avoid a significant difference in curative effect.

A fat-soluble extract of Brucea javanica L. Merr is employed in preparing medicines for promoting peripheral nerve regeneration. The fat-soluble extract of Brucea javanica L. Merr is obtained by extraction with a mixed solution of absolute ethanol and ethyl acetate. The present invention finds through research that the fat-soluble extract of Brucea javanica L. Merr promotes the growth of peripheral DRG neurons and neurites, and promotes the division and proliferation of the glial cells, that is, Schwann cells, of the peripheral nervous system, suggesting that the fat-soluble extract of Brucea javanica L. Merr has the effect of promoting peripheral nerve regeneration.

The present invention relates to a multi-channel conductive nerve repair catheter with fluorescence characteristics and a preparation method thereof. The arrayed nanofibers are biodegradable aliphatic polyester nanofibers containing carbon nanotubes with fluorescent properties. The catheter prepared by the invention has photoluminescent properties and electrical conductivity, can be imaged in vivo, and can be used for nerve regeneration and repair. The parallel multi-channel structure of the catheter provides a certain mechanical strength, the oriented conductive fibers can promote the proliferation and differentiation of nerve cells, and the fluorescent carbon nanotubes provide an effective characterization of its existence and whereabouts in the regenerative nerve. means.